Cost avoidance from dose rounding biologic and cytotoxic antineoplastics.

about

Cost avoidance from dose rounding biologic and cytotoxic antineoplastics.

Item

http://www.wikidata.org/entity/Q39901051

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Cost avoidance from dose rounding biologic and cytotoxic antineoplastics.

@en

Cost avoidance from dose rounding biologic and cytotoxic antineoplastics.

@nl

type

Item

label

Cost avoidance from dose rounding biologic and cytotoxic antineoplastics.

@en

Cost avoidance from dose rounding biologic and cytotoxic antineoplastics.

@nl

prefLabel

Cost avoidance from dose rounding biologic and cytotoxic antineoplastics.

@en

Cost avoidance from dose rounding biologic and cytotoxic antineoplastics.

@nl

P1476

Cost avoidance from dose rounding biologic and cytotoxic antineoplastics.

@en

P2093

Corey M Ballmer

http://www.w3.org/2001/XMLSchema#string

Paul W Athmann

http://www.w3.org/2001/XMLSchema#string

Polly E Kintzel

http://www.w3.org/2001/XMLSchema#string

Thomas H Vandyke

http://www.w3.org/2001/XMLSchema#string

P2860

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.

Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer.

Population pharmacokinetics of bevacizumab in children with osteosarcoma: implications for dosing.

A new frontier in haematology - combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drug

Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.

Projections of the cost of cancer care in the United States: 2010-2020.

Phase I studies of chemotherapeutic agents in cancer patients: a review of the designs.

Delivering high-quality and affordable care throughout the cancer care continuum.

Cost savings from dose rounding of biologic anticancer agents in adults.

Rounding rituximab dose to nearest vial size.

P304

379-383

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1078155216639756

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27000279

http://www.w3.org/2001/XMLSchema#string

P921

cytotoxicity